Northwest Biotherapeutics

Northwest Biotherapeutics has begun building its first Grade C manufacturing suite in the UK, aiming to significantly increase DCVax® production capacity. This transition, facilitated by their Flaskworks system, allows for simultaneous manufacturing of multiple patient products, improving efficiency compared to Grade B suites. The new suite is expected to be operational in Q2 next year. This expansion supports large-scale production of DCVax® personalized immune therapies, including DCVax-L for glioblastoma, for which the company has already submitted a Market Authorization Application in the UK.

Northwest Biotherapeutics (NWBO) announced the passing of Senior Vice President and General Counsel, Les Goldman. Goldman was a key contributor to NWBO, a biotech firm focused on personalized immune therapies for solid tumor cancers, particularly via its DCVax® platform. NWBO is advancing DCVax®-L for glioblastoma, with UK regulatory review underway. They are also developing DCVax®-Direct for inoperable solid tumors. His responsibilities are being assumed by existing management.